Scientific research company The Kavli Foundation revealed on Tuesday the election of Kevin Moses, PhD in Genetics, as the vice president of its Science Programmes.
Effective 1 December 2018, Dr Moses will lead the company's flagship programmes in astrophysics, nanoscience, neuroscience and theoretical physics, including the 20 Kavli Institutes around the world, the Kavli science meetings programme, summer schools, as well as the partnerships with national science agencies, scientific societies and other philanthropies. He will develop and implement fundamental science and technology projects to support scientists and their work.
Currently, Dr Moses serves as science officer at the Chan Zuckerberg Initiative, where he helped to establish its programmes, partnerships and grant-making initiatives.
Most recently, Dr Moses has worked for five years at the Wellcome Trust, the UK's largest charitable foundation.
Previously, Dr Moses was the associate director for Science and Training, chief academic officer as well as founder of Janelia, a research campus of the Howard Hughes Medical Institute dedicated to understanding the brain.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA